Cell fusion: from hybridoma to dendritic cell-based vaccine

References

• Pardoll D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol.21, 807–839 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Shedding light on tumor immunotherapy of cancer. N. Engl. J. Med.350, 1461–1463 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Med.10, 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol.3(8), 630–641 (2003).
   PubMed Web of Science ®Google Scholar
• Primakoff P, Myles DG. Penetration, adhesion, and fusion in mammalian sperm-egg interaction. Science296(5576), 2183–2185 (2002).
   PubMed Web of Science ®Google Scholar
• Chen EH, Olson EN. Towards a molecular pathway for myoblast fusion in Drosophila.Trends Cell Biol.14(8), 452–460 (2004).
   PubMedGoogle Scholar
• Stolzing A, Hescheler J, Sethe S. Fusion and regenerative therapies: is immortality really recessive? Rejuvenation Res.10(4), 571–586 (2007).
   Google Scholar
• Guccion JG, Enzinger FM. Malignant giant cell tumor of soft parts. An analysis of 32 cases. Cancer29(6), 1518–1529 (1972).
   PubMed Web of Science ®Google Scholar
• Okada Y, Tadokoro J. The distribution of cell fusion capacity among several cell strains or cells caused by HVJ. Exp. Cell Res.32, 417–430 (1963).
   Google Scholar
• Okada Y, Yamada K, Tadokoro J. Effect of antiserum on the cell fusion reaction caused by HVJ. Virology22, 397–409 (1964).
   Google Scholar
• Okada Y, Kim J, Maeda Y, Koseki I. Specific movement of cell membranes fused with HVJ (Sendai virus). Proc. Natl Acad. Sci. USA71(5), 2043–2047 (1974).
   Google Scholar
• Furusawa M, Nishimura T, Yamaizumi M, Okada Y. Injection of foreign substances into single cells by cell fusion. Nature249(456), 449–450 (1974).
   PubMed Web of Science ®Google Scholar
• Frye LD, Edidin M. The rapid intermixing of cell surface antigens after formation of mouse-human heterokaryons. J. Cell Sci.7(2), 319–335 (1970).
   PubMed Web of Science ®Google Scholar
• Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science175(23), 720–731 (1972).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Tome P, Lijnzaad P. The radiation hybrid database. Nucleic Acids Res.27(1), 115–118 (1999).
   Google Scholar
• Islam MQ, Meirelles Lda S, Nardi NB, Magnusson P, Islam K. Polyethylene glycol-mediated fusion between primary mouse mesenchymal stem cells and mouse fibroblasts generates hybrid cells with increased proliferation and altered differentiation. Stem Cells Dev.15(6), 905–919 (2006).
   Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature256(5517), 495–497 (1975).
   PubMed Web of Science ®Google Scholar
• Galfre G, Howe SC, Milstein C, Butcher GW, Howard JC. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature266(5602), 550–552 (1977).
   PubMed Web of Science ®Google Scholar
• Margulies DH. Monoclonal antibodies: producing magic bullets by somatic cell hybridization. J. Immunol.174(5), 2451–2452 (2005).
   Google Scholar
• Milstein C. The hybridoma revolution: an offshoot of basic research. Bioessays21(11), 966–973 (1999).
   PubMed Web of Science ®Google Scholar
• Davidson RL, Gerald PS. Improved techniques for the induction of mammalian cell hybridization by polyethylene glycol. Somatic Cell Genet.2(2), 165–176 (1976).
   PubMedGoogle Scholar
• Kuby J. Hybridoma and monoclonal antibody. In: Immunology (Volume 7). Kuby J (Ed.). WH Freeman and Company, NY, USA 141–156 (1992).
   Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol.9, 271–296 (1991).
   PubMed Web of Science ®Google Scholar
• Steinman RM. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai. J. Med.68(3), 106–166 (2001).
   PubMedGoogle Scholar
• Young JW, Koulova L, Soergel SA et al. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro.J. Clin. Invest.90(1), 229–237 (1992).
   PubMed Web of Science ®Google Scholar
• Inaba K, Witmer-Pack M, Inaba M et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro.J. Exp. Med.180(5), 1849–1860 (1994).
   PubMed Web of Science ®Google Scholar
• Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med.183(1), 7–11 (1996).
   PubMed Web of Science ®Google Scholar
• Inaba K, Pack M, Inaba M et al. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J. Exp. Med.186(5), 665–672 (1997).
   PubMed Web of Science ®Google Scholar
• Thery C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr. Opin. Immunol.13(1), 45–51 (2001).
   PubMed Web of Science ®Google Scholar
• Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med.183(1), 283–287 (1996).
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med.1(12), 1297–1302 (1995).
   PubMed Web of Science ®Google Scholar
• Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med.183(1), 317–322 (1996).
   PubMed Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med.4(3), 328–332 (1998).
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med.2(1), 52–58 (1996).
   PubMed Web of Science ®Google Scholar
• Loveland BE, Zhao A, White S et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a Phase I trial in patients with adenocarcinoma. Clin. Cancer Res.12(3 Pt 1), 869–877 (2006).
   PubMed Web of Science ®Google Scholar
• Gong J, Chen L, Chen D et al. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther.4(10), 1023–1028 (1997).
   PubMed Web of Science ®Google Scholar
• Tang CK, Lodding J, Minigo G et al. Mannan-mediated gene delivery for cancer immunotherapy. Immunology120(3), 325–335 (2007).
   Google Scholar
• Koido S, Kashiwaba M, Chen D et al. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol.165(10), 5713–5719 (2000).
   PubMed Web of Science ®Google Scholar
• Specht JM, Wang G, Do MT et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med.186(8), 1213–1221 (1997).
   PubMed Web of Science ®Google Scholar
• Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med.2(10), 1122–1128 (1996).
   PubMed Web of Science ®Google Scholar
• Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med.3(5), 558–561 (1997).
   PubMed Web of Science ®Google Scholar
• Gong J, Koido S, Chen D et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood99(7), 2512–2517 (2002).
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang W, Chan T, Saxena A, Xiang J. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk. Res.26(8), 757–763 (2002).
   PubMed Web of Science ®Google Scholar
• Lindner M, Schirrmacher V. Tumour cell–dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols. Eur. J. Clin. Invest.32(3), 207–217 (2002).
   PubMed Web of Science ®Google Scholar
• Homma S, Toda G, Gong J, Kufe D, Ohno T. Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J. Gastroenterol.36(11), 764–771 (2001).
   PubMed Web of Science ®Google Scholar
• Cao X, Zhang W, Wang J et al. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte–macrophage colony-stimulating factor genetically modified dendritic cells. Immunology97(4), 616–625 (1999).
   PubMed Web of Science ®Google Scholar
• Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol.161(10), 5516–5524 (1998).
   PubMed Web of Science ®Google Scholar
• Hayashi T, Tanaka H, Tanaka J et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin. Immunol.104(1), 14–20 (2002).
   PubMed Web of Science ®Google Scholar
• Xia J, Tanaka Y, Koido S et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J. Immunol.170(4), 1980–1986 (2003).
   PubMed Web of Science ®Google Scholar
• Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ. Tumor-derived TGF-b reduces the efficacy of dendritic cell/tumor fusion vaccine. J. Immunol.170(7), 3806–3811 (2003).
   PubMed Web of Science ®Google Scholar
• Takeda A, Homma S, Okamoto T, Kufe D, Ohno T. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity. Eur. J. Clin. Invest.33(10), 897–904 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang JK, Li J, Zhang J, Chen HB, Chen SB. Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo.World J. Gastroenterol.9(3), 479–484 (2003).
   PubMed Web of Science ®Google Scholar
• Li J, Holmes LM, Franek KJ et al. Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol. Immunother.50(9), 456–462 (2001).
   PubMed Web of Science ®Google Scholar
• Xia D, Chan T, Xiang J. Dendritic cell/myeloma hybrid vaccine. Methods Mol. Med.113, 225–233 (2005).
   PubMedGoogle Scholar
• Homma S, Kikuchi T, Ishiji N et al. Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Eur. J. Clin. Invest.35(4), 279–286 (2005).
   PubMed Web of Science ®Google Scholar
• Kao JY, Zhang M, Chen CM, Chen JJ. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol. Lett.101(2), 154–159 (2005).
   PubMed Web of Science ®Google Scholar
• Ogawa F, Iinuma H, Okinaga K. Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells. Scand. J. Immunol.59(5), 432–439 (2004).
   PubMed Web of Science ®Google Scholar
• Akasaki Y, Kikuchi T, Homma S et al. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J. Immunother.24(2), 106–113 (2001).
   Web of Science ®Google Scholar
• Scott-Taylor TH, Pettengell R, Clarke I et al. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim. Biophys. Acta1500(3), 265–279 (2000).
   PubMed Web of Science ®Google Scholar
• Tanaka H, Shimizu K, Hayashi T, Shu S. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell. Immunol.220(1), 1–12 (2002).
   PubMed Web of Science ®Google Scholar
• Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol. Ther.7(4), 498–505 (2003).
   PubMed Web of Science ®Google Scholar
• Jantscheff P, Spagnoli G, Zajac P, Rochlitz CF. Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells. Cancer Immunol. Immunother.51(7), 367–375 (2002).
   PubMed Web of Science ®Google Scholar
• Goddard RV, Prentice AG, Copplestone JA, Kaminski ER. In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids. Clin. Exp. Immunol.131(1), 82–89 (2003).
   PubMed Web of Science ®Google Scholar
• Marten A, Renoth S, Heinicke T et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther.14(5), 483–494 (2003).
   PubMed Web of Science ®Google Scholar
• Trevor KT, Cover C, Ruiz YW et al. Generation of dendritic cell–tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol. Immunother.53(8), 705–714 (2004).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Fukuhara T, Tanaka M et al. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin. Cancer Res.11(1), 58–66 (2005).
   PubMed Web of Science ®Google Scholar
• Trefzer U, Herberth G, Wohlan K et al. Tumour–dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine23(17–18), 2367–2373 (2005).
   PubMed Web of Science ®Google Scholar
• Shimizu K, Kuriyama H, Kjaergaard J et al. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J. Immunother.27(4), 265–272 (2004).
   PubMed Web of Science ®Google Scholar
• Phan V, Errington F, Cheong SC et al. A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell–tumor cell hybrid vaccines. Nat. Med.9(9), 1215–1219 (2003).
   PubMedGoogle Scholar
• Hiraoka K, Yamamoto S, Otsuru S et al. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J. Immunol.173(7), 4297–4307 (2004).
   Google Scholar
• Steinman RM, Swanson J. The endocytic activity of dendritic cells. J. Exp. Med.182(2), 283–288 (1995).
   PubMed Web of Science ®Google Scholar
• Watts C. The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat. Immunol.5(7), 685–692 (2004).
   PubMed Web of Science ®Google Scholar
• Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol.19, 47–64 (2001).
   PubMed Web of Science ®Google Scholar
• Berard F, Blanco P, Davoust J et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med.192(11), 1535–1544 (2000).
   PubMed Web of Science ®Google Scholar
• Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TN. Antigen bias in T cell cross-priming. Science304(5675), 1314–1317 (2004).
   PubMed Web of Science ®Google Scholar
• Koido S, Ohana M, Liu C et al. Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation. Clin. Immunol.113(3), 261–269 (2004).
   PubMed Web of Science ®Google Scholar
• Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell–leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immunother.51(6), 299–310 (2002).
   PubMed Web of Science ®Google Scholar
• Gong J, Chen D, Kashiwaba M et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl Acad. Sci. USA95(11), 6279–6283 (1998).
   PubMed Web of Science ®Google Scholar
• Lespagnard L, Mettens P, Verheyden AM et al. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int. J. Cancer.76(2), 250–258 (1998).
   PubMed Web of Science ®Google Scholar
• Koido S, Hara E, Homma S et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res.11(21), 7891–7900 (2005).
   PubMedGoogle Scholar
• Koido S, Tanaka Y, Chen D, Kufe D, Gong J. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J. Immunol.168(5), 2111–2117 (2002).
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood100(1), 230–237 (2002).
   PubMed Web of Science ®Google Scholar
• Satthaporn S, Robins A, Vassanasiri W et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol. Immunother.53(6), 510–518 (2004).
   PubMed Web of Science ®Google Scholar
• Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res.63(15), 4497–4506 (2003).
   PubMed Web of Science ®Google Scholar
• Bevan MJ. Helping the CD8+ T-cell response. Nat. Rev. Immunol.4(8), 595–602 (2004).
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J. Immunol.170(10), 5317–5325 (2003).
   PubMed Web of Science ®Google Scholar
• Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol. Immunother.53(11), 963–977 (2004).
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Rezvany MR, Virving L et al. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia17(5), 894–899 (2003).
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA90(8), 3539–3543 (1993).
   PubMed Web of Science ®Google Scholar
• Hung K, Hayashi R, Lafond-Walker A et al. The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med.188(12), 2357–2368 (1998).
   PubMed Web of Science ®Google Scholar
• Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med.187(5), 693–702 (1998).
   PubMed Web of Science ®Google Scholar
• Marzo AL, Kinnear BF, Lake RA et al. Tumor-specific CD4+ T cells have a major ‘post-licensing’ role in CTL mediated anti-tumor immunity. J. Immunol.165(11), 6047–6055 (2000).
   PubMed Web of Science ®Google Scholar
• Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res.59(5), 1071–1079 (1999).
   PubMed Web of Science ®Google Scholar
• Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol.49, 281–355 (1991).
   PubMed Web of Science ®Google Scholar
• Chaux P, Vantomme V, Stroobant V et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4+ T lymphocytes. J. Exp. Med.189(5), 767–778 (1999).
   PubMed Web of Science ®Google Scholar
• Mumberg D, Monach PA, Wanderling S et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl Acad. Sci. USA96(15), 8633–8638 (1999).
   PubMed Web of Science ®Google Scholar
• Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN γ receptor expression by nonhematopoietic cells. Immunity12(6), 677–686 (2000).
   PubMed Web of Science ®Google Scholar
• Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature393(6684), 474–478 (1998).
   PubMed Web of Science ®Google Scholar
• Mitchison NA. An exact comparison between the efficiency of two- and three-cell-type clusters in mediating helper activity. Eur. J. Immunol.20(3), 699–702 (1990).
   Google Scholar
• Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med.186(1), 65–70 (1997).
   PubMed Web of Science ®Google Scholar
• Behrens G, Li M, Smith CM et al. Helper T cells, dendritic cells and CTL immunity. Immunol. Cell Biol.82(1), 84–90 (2004).
   Google Scholar
• Celluzzi CM, Falo LD, Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol.160(7), 3081–3085 (1998).
   PubMed Web of Science ®Google Scholar
• Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell. Immunol.225(2), 65–74 (2003).
   PubMed Web of Science ®Google Scholar
• Gong J, Apostolopoulos V, Chen D et al. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology101(3), 316–324 (2000).
   PubMed Web of Science ®Google Scholar
• Krause SW, Neumann C, Soruri A et al. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J. Immunother.25(5), 421–428 (2002).
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Irie M et al. Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother.50(7), 337–344 (2001).
   PubMed Web of Science ®Google Scholar
• Avigan D, Vasir B, Gong J et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res.10(14), 4699–4708 (2004).
   PubMed Web of Science ®Google Scholar
• Avigan DE, Vasir B, George DJ et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother.30(7), 749–761 (2007).
   PubMed Web of Science ®Google Scholar
• Haenssle HA, Krause SW, Emmert S et al. Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a Phase I/II study. J. Immunother.27(2), 147–155 (2004).
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer5(4), 263–274 (2005).
   PubMed Web of Science ®Google Scholar
• Schnare M, Barton GM, Holt AC et al. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol.2(10), 947–950 (2001).
   PubMed Web of Science ®Google Scholar
• Michelsen KS, Aicher A, Mohaupt M et al. The role of Toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J. Biol. Chem.276(28), 25680–25686 (2001).
   Google Scholar
• Kaisho T, Akira S. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol.22(2), 78–83 (2001).
   PubMed Web of Science ®Google Scholar
• Xia D, Li F, Xiang J. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biother. Radiopharm.19(3), 322–330 (2004).
   PubMedGoogle Scholar
• Vasir B, Wu Z, Crawford K et al. Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J. Immunol.181(1), 808–821 (2008).
   PubMed Web of Science ®Google Scholar
• Ladoire S, Arnould L, Apetoh L et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3+ regulatory T cells. Clin. Cancer Res.14(8), 2413–2420 (2008).
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol.6(4), 295–307 (2006).
   PubMed Web of Science ®Google Scholar
• Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol. Immunother. (2008) [Epub ahead of print] DOI: 10.1007/s00262-008-0505-6.
   Google Scholar
• Iinuma T, Homma S, Noda T et al. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J. Clin. Invest.113(9), 1307–1317 (2004).
   PubMed Web of Science ®Google Scholar
• Coughlin CM, Wysocka M, Kurzawa HL et al. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res.55(21), 4980–4987 (1995).
   PubMed Web of Science ®Google Scholar
• Mountford AP, Anderson S, Wilson RA. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant. J. Immunol.156(12), 4739–4745 (1996).
   PubMed Web of Science ®Google Scholar
• Grohmann U, Bianchi R, Ayroldi E et al. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J. Immunol.158(8), 3593–3602 (1997).
   PubMed Web of Science ®Google Scholar
• Okamoto M, Furuichi S, Nishioka Y et al. Expression of Toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res.64(15), 5461–5470 (2004).
   PubMedGoogle Scholar
• Heckelsmiller K, Beck S, Rall K et al. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol.32(11), 3235–3245 (2002).
   PubMed Web of Science ®Google Scholar
• Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res.63(14), 4112–4118 (2003).
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res.11(11), 4160–4167 (2005).
   PubMed Web of Science ®Google Scholar
• Koido S, Hara E, Homma S et al. Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J. Immunol.178(1), 613–622 (2007).
   PubMedGoogle Scholar
• Koido S, Hara E, Homma S et al. Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J. Immunol.179(7), 4874–4883 (2007).
   PubMedGoogle Scholar
• Du YC, Lin P, Zhang J et al. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses. Tissue Antigens67(5), 368–376 (2006).
   Google Scholar
• Gong J, Nikrui N, Chen D et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol.165(3), 1705–1711 (2000).
   PubMed Web of Science ®Google Scholar
• Gong J, Avigan D, Chen D et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl Acad. Sci. USA97(6), 2715–2718 (2000).
   PubMed Web of Science ®Google Scholar
• Raje N, Hideshima T, Davies FE et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br. J. Haematol.25(3), 343–352 (2004).
   Google Scholar
• Gong J, Koido S, Kato Y et al. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk. Res.28(12), 1303–1312 (2004).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Koido S, Xia J et al. Development of antigen-specific CD8+ CTL in MHC class I-deficient mice through CD4 to CD8 conversion. J. Immunol.172(12), 7848–7858 (2004).
   Google Scholar
• Tamai H, Watanabe S, Zheng R et al. Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic–tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin. Immunol.127(1), 66–77 (2008).
   PubMed Web of Science ®Google Scholar
• Homma S, Matai K, Irie M et al. Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma. J. Gastroenterol.38(10), 989–994 (2003).
   PubMed Web of Science ®Google Scholar
• Koido S, Hara E, Torii A et al. Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells. Int. J. Cancer117(4), 587–595 (2005).
   Google Scholar
• Gottfried E, Krieg R, Eichelberg C et al. Characterization of cells prepared by dendritic cell-tumor cell fusion. Cancer Immun.2, 15 (2002).
   PubMedGoogle Scholar
• Bischoff R, Eisert RM, Schedel I, Vienken J, Zimmerman U. Human hybridoma cells produced by electro-fusion. FEBS Lett.147(1), 64–68 (1982).
   PubMed Web of Science ®Google Scholar
• Gabrijel M, Repnik U, Kreft M et al. Quantification of cell hybridoma yields with confocal microscopy and flow cytometry. Biochem. Biophys. Res. Commun.314(3), 717–723 (2004).
   Google Scholar
• Neil GA, Zimmermann U. Electrofusion. Methods Enzymol.220, 174–196 (1993).
   Google Scholar
• Kinzler ER, Compton T. Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J. Virol.79(12), 7827–7837 (2005).
   Google Scholar
• Plattet P, Rivals JP, Zuber B et al. The fusion protein of wild-type canine distemper virus is a major determinant of persistent infection. Virology337(2), 312–326 (2005).
   Google Scholar
• Negrete OA, Levroney EL, Aguilar HC et al. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature436(7049), 401–405 (2005).
   PubMed Web of Science ®Google Scholar
• Lamb RA, Kolakofsky D. Paramyxoviridae: the viruses and their replication. Fields Virology 4th1305–1340 (2001).
   Google Scholar
• Pare ME, Gauthier S, Landry S et al. A new sensitive and quantitative HTLV-I-mediated cell fusion assay in T cells. Virology338(2), 309–322 (2005).
   Google Scholar
• Bateman A, Bullough F, Murphy S et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res.60(6), 1492–1497 (2000).
   PubMed Web of Science ®Google Scholar
• Linardakis E, Bateman A, Phan V et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell–tumor cell fusion. Cancer Res.62(19), 5495–5504 (2002).
   PubMed Web of Science ®Google Scholar
• Ebert O, Shinozaki K, Kournioti C et al. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res.64(9), 3265–3270 (2004).
   PubMed Web of Science ®Google Scholar
• Bateman AR, Harrington KJ, Kottke T et al. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res.62(22), 6566–6578 (2002).
   PubMed Web of Science ®Google Scholar
• Holmes LM, Li J, Sticca RP, Wagner TE, Wei Y. A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphoctye responses using instant dentritomas. J. Immunother.24(2), 122–129 (2001).
   Web of Science ®Google Scholar
• Chen D, Xia J, Tanaka Y et al. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology109(2), 300–307 (2003).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Koido S, Chen D et al. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin. Immunol.101(2), 192–200 (2001).
   PubMed Web of Science ®Google Scholar
• Walden P. Hybrid cell vaccination for cancer immunotherapy. Adv Exp Med Biol465, 347–354 (2000).
   Google Scholar
• Fabre JW. The allogeneic response and tumor immunity. Nat. Med.7(6), 649–652 (2001).
   PubMed Web of Science ®Google Scholar
• Ford WL, Atkins RC. The proportion of lymphocytes capable of recognizing strong transplantation antigens in vivo. Adv. Exp. Med. Biol.29(0), 255–262 (1973).
   Google Scholar
• Ford WL, Simmonds SJ, Atkins RC. Early cellular events in a systemic graft-vs.-host reaction. II. Autoradiographic estimates of the frequency of donor lymphocytes which respond to each Ag-B-determined antigenic complex. J. Exp. Med.141(3), 681–696 (1975).
   Google Scholar
• Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu. Rev. Immunol.11, 385–402 (1993).
   PubMed Web of Science ®Google Scholar
• Lundqvist A, Palmborg A, Bidla G et al. Allogeneic tumor–dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses. Med. Oncol.21(2), 155–165 (2004).
   Google Scholar
• Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J. Clin.50(1), 7–33 (2000).
   PubMed Web of Science ®Google Scholar
• Chomez P, De Backer O, Bertrand M et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res.61(14), 5544–5551 (2001).
   PubMed Web of Science ®Google Scholar
• Koido S, Tanaka Y, Tajiri H, Gong J. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. Vaccine25(14), 2610–2619 (2007).
   PubMed Web of Science ®Google Scholar